Drug
Risdiplam clinical trials
Also written RO7034067 and Evrysdi.
- studies test it
- 14
- open now
- 1
- in phase 3
- 0
- first study started
- 2016
Keep track of what changes. Save the Risdiplam studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2016 (3)
| Year | Studies |
|---|---|
| 2016 | 3 |
| 2017 | 3 |
| 2019 | 3 |
| 2022 | 2 |
| 2024 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 5
- Phase 4
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 1
Hoffmann-La Roche (12) · Clinic for Special Children (1) · Genentech, Inc. (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Risdiplam is read from its arms, and is right about nine times in ten.
Testing it · 14
- A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene TherapyRecruitingPhase 4Hoffmann-La RocheNCT05861986Written as Risdiplam
- A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene TherapyActive, not recruitingPhase 4Hoffmann-La RocheNCT05861999Written as Risdiplam
- Long-term Follow-up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA)CompletedPhase 4Genentech, Inc.NCT05232929Written as Risdiplam
- A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular AtrophyActive, not recruitingPhase 2Hoffmann-La RocheNCT03779334Written as Risdiplam
- A Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular AtrophyCompletedPhase 2Hoffmann-La RocheNCT05808764Written as Risdiplam
- A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular AtrophyCompletedPhase 2Hoffmann-La RocheNCT03032172Written as Risdiplam
- Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular AtrophyCompletedPhase 2Hoffmann-La RocheNCT02913482Written as Risdiplam
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) ParticipantsCompletedPhase 2Hoffmann-La RocheNCT02908685Written as Risdiplam
- Risdiplam in Patients With Spinal Muscular Atrophy Previously Treated With NusinersenActive, not recruitingPhase 4Clinic for Special ChildrenNCT05522361Written as Risdiplam
- A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety and Tolerability of a Single Oral Dose of Risdiplam Compared to Matched Healthy Participants With Normal Hepatic FunctionCompletedPhase 1Hoffmann-La RocheNCT03920865Written as Risdiplam
- A Drug-drug Interaction Study With Risdiplam Multiple Dose and Midazolam in Healthy ParticipantsCompletedPhase 1Hoffmann-La RocheNCT03988907Written as Risdiplam
- A Study Investigating the Excretion Balance, Pharmacokinetics and Metabolism of a Single Oral Dose of [14C]-Labeled Risdiplam (RO7034067) in Healthy Male ParticipantsCompletedPhase 1Hoffmann-La RocheNCT03036501Written as [^14C]-Risdiplam
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Risdiplam (RO7034067) in Healthy Japanese ParticipantsCompletedPhase 1Hoffmann-La RocheNCT03040635Written as Risdiplam
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Risdiplam (RO7034067) Given by Mouth in Healthy VolunteersCompletedPhase 1Hoffmann-La RocheNCT02633709Written as Risdiplam
Given in every arm · 3 — Risdiplam is usual care beside what is tested
- A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular AtrophyRecruitingPhase 2Scholar Rock, Inc.NCT07047144Written as Risdiplam
- A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular AtrophyActive, not recruitingPhase 2/3Hoffmann-La RocheNCT05115110Written as Risdiplam
- Bioavailability and Bioequivalence of Two Risdiplam Tablets in Healthy ParticipantsCompletedPhase 1Hoffmann-La RocheNCT04718181Written as risdiplam
Codes
What other systems call Risdiplam · ClinicalTrials.gg INT001052
- MeSH (NLM) C000629884RisdiplamConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 76RS4S2ET1RISDIPLAMConfirmed FDA, NLM, Wikidata
- RxNorm 2390935One source FDA
- Wikidata Q48969152risdiplamConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C167001RisdiplamOne source FDA
- DrugBank DB15305One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000629884 | Risdiplam | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 76RS4S2ET1 | RISDIPLAM | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2390935 | — | One source FDA |
| Wikidata | Q48969152 | risdiplam | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C167001 | Risdiplam | One source FDA |
| DrugBank | DB15305 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.